Ottobock stock faces a lawsuit over Russia business disclosures

Published on 10/07/2026 at 13:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Ottobock stock was at EUR 50.80 on October 7, 2026, down 0.78 percent. A shareholder group is challenging disclosures on the companys Russia business.

Ottobock, DE000BCK2223, Illustration mit AI erstellt.

Ottobock stock (ISIN DE000BCK2223) was trading at EUR 50.80 on Xetra on October 7, 2026, down 0.78 percent. The current catalyst is a legal challenge over disclosures concerning the medical technology group's Russia business, as finanzen.ch reported on October 7, 2026.

Russia case reaches court

The Deutsche Schutzgemeinschaft für Wertpapierbesitz is pursuing a prospectus liability case against Ottobock. Tagesschau reported on September 25, 2026, that the dispute concerns whether the prospectus gave a sufficiently complete picture of the Russia business. Ottobock rejected the criticism and reaffirmed the integrity of its capital-market information.

The issue has a measurable earnings connection. The October 7 report said Russia still represented 10 percent of Ottobock's revenue, making the legal dispute relevant to both disclosure standards and geographic exposure.

Half-year revenue reached EUR 610 million

Ottobock generated EUR 610 million in revenue in the first half of 2026, according to HNA. The figure gives the legal dispute a current operating context because it belongs to the latest reported interim period and is not an old fiscal-year comparison.

Ottobock's investor-relations page describes a business spanning prosthetics, neuro-orthotics and exoskeletons, with nearly 9,300 full-time employees, operations in 45 countries and more than 430 patient-care centers. Its fiscal-year 2025 figures included EUR 53.74 million of adjusted core-business EBITDA and a 22.9 million euro adjusted group profit, with both measures higher than the prior year, according to Ottobock.

Analysts still see upside

The analyst picture remains constructive but divided. MarketScreener listed an average Buy rating from 8 analysts, an average target of EUR 80.38 and a 44.56 percent gap to the EUR 55.60 reference close shown on its page. Jefferies maintained a Buy rating and an EUR 83 target on September 15, 2026.

A more cautious view came from Berenberg, which maintained Hold with an EUR 66 target on September 11, 2026, as reported by finanzen.net. The spread between EUR 66 and EUR 83 shows that the Russia disclosure case is not the only variable shaping expectations; execution after the first-half update remains central.

Ottobock stock trades below EUR 51

Ottobock stock was last at EUR 50.80 on Xetra on October 7, 2026. The dated price and the latest half-year revenue figure put the legal risk beside a still-growing operating base, rather than treating the lawsuit as an isolated headline.